Patents matching “regimen”

US 10335460

IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Jul 2, 2019 · Expires Jun 27, 2039

US 9498468

Rhinitis treatment regimens

Pharmaceutical Design, LLC · Granted Nov 22, 2016 · Expires Nov 17, 2036

US 9314486

Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation

Montefiore Medical Center · Granted Apr 19, 2016 · Expires Apr 14, 2036

US 9095608

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

The Regents of the University of Colorado · Granted Aug 4, 2015 · Expires Jul 30, 2035

US 8450299

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Teva Womans's Health, Inc. · Granted May 28, 2013 · Expires May 23, 2033

US 8415332

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Teva Womans's Health, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

US 8361471

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

The Regents of the University of Colorado · Granted Jan 29, 2013 · Expires Jan 24, 2033

US 8137672

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

The Regents of the University of Colorado · Granted Mar 20, 2012 · Expires Mar 15, 2032

US 7993648

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

The Regents of the University of Colorado · Granted Aug 9, 2011 · Expires Aug 4, 2031

US 7855190

Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration

TEVA WOMEN'S HEALTH, INC. · Granted Dec 21, 2010 · Expires Dec 16, 2030

US 7772219

Methods of hormonal treatment utilizing extended cycle contraceptive regimens

TEVA WOMEN'S HEALTH, INC. · Granted Aug 10, 2010 · Expires Aug 5, 2030

US 7541331

Surfactant treatment regimen

Discovery Laboratories, Inc. · Granted Jun 2, 2009 · Expires May 28, 2029

US 6759408

Combination regimens using progesterone receptor modulators

Ligand Pharmaceuticals Incorporated · Granted Jul 6, 2004 · Expires Jul 1, 2024

US 6544970

Cyclic regimens utilizing indoline derivatives

Ligand Pharmaceuticals Incorporated · Granted Apr 8, 2003 · Expires Apr 3, 2023

US 6503939

Combination regimens using 3,3-substituted indoline derivatives

Ligand Pharmaceuticals Incorporated · Granted Jan 7, 2003 · Expires Jan 2, 2023

US 6498154

Cyclic regimens using quinazolinone and benzoxazine derivatives

Ligand Pharmaceuticals Incorporated · Granted Dec 24, 2002 · Expires Dec 19, 2022

US 6462032

Cyclic regimens utilizing indoline derivatives

Ligand Pharmaceuticals Incorporated · Granted Oct 8, 2002 · Expires Oct 3, 2022

US 6444668

Combination regimens using progesterone receptor modulators

Ligand Pharmaceuticals Incorporated · Granted Sep 3, 2002 · Expires Aug 29, 2022

US 6399593

Cyclic regimens using cyclic urea and cyclic amide derivatives

Ligand Pharmaceuticals Incorporated · Granted Jun 4, 2002 · Expires May 30, 2022

US 6380178

Cyclic regimens using cyclocarbamate and cyclic amide derivatives

Ligand Pharmaceuticals Incorporated · Granted Apr 30, 2002 · Expires Apr 25, 2022

US 6329416

Combination regimens using 3,3-substituted indoline derivatives

Ligand Pharmaceuticals Incorporated · Granted Dec 11, 2001 · Expires Dec 6, 2021

US 6319912

Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides

Ligand Pharmaceuticals Incorporated · Granted Nov 20, 2001 · Expires Nov 15, 2021